Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.40 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.35 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 2/20 | 0.35 |
| ▸ | PRKDC | P78527 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | NPY1R | P25929 | 1/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | ACACA | Q13085 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7613860 | 0.86 | TP53 (0.38) | DRD2 | |
| SCHEMBL7607374 | 0.83 | DRD2 (0.36) | DRD2RORC | |
| SCHEMBL4500892 | 0.81 | P2RY14 (0.38) | DRD2P2RY14MAPK14PRKDCCNR2 | |
| SCHEMBL12513701 | 0.79 | CNR2 (0.42) | DRD2P2RY14MAPK14RORCPRKDC | |
| SCHEMBL1845748 | 0.76 | MAPK14 (0.39) | DRD2P2RY14MAPK14PRKDCCNR2 | |
| SCHEMBL5001090 | 0.72 | TOP1 (0.40) | DRD2MAPK14PRKDCCNR2ACHE | |
| SCHEMBL5000911 | 0.72 | TOP1 (0.40) | DRD2MAPK14PRKDCCNR2ACHE | |
| SCHEMBL15385155 | 0.72 | TOP1 (0.40) | DRD2MAPK14PRKDCCNR2ACHE | |
| SCHEMBL8536509 | 0.71 | RAB9A (0.44) | P2RY14 | |
| SCHEMBL14262464 | 0.69 | CNR2 (0.40) | DRD2MAPK14RORCPRKDCCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020198254-A1 | Polyamide analogs | GENELABS TECHNOLOGIES, INC. | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198254-A1 | Polyamide analogs | CYP51A1, HDAC6, ERG28 | DRD2 4627/4885P2RY14 2498/4885MAPK14 3761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.